Ianalumab

DB16666InvestigationalProtein Based Therapies

Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 13C
Curator reviewed
Code names: VAY-736

Resolves to

Compound

Targets

What you can answer from here — as of March 25, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

30Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ianalumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.